← Back to Screener
BioLineRX Ltd (BLRX)
Price$3.48
Value ScoreB
Growth ScoreF
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-26.46%
Price vs S&P 500 (4W)8.36%
VGM Score45.46
Market Capitalization$39.31M
All Metrics
Book Value / Share (Quarterly)$0.01
P/TBV (Annual)8.12x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.00
Price vs S&P 500 (YTD)-3.46%
Gross Margin (TTM)80.51%
Net Profit Margin (TTM)-171.44%
EPS (TTM)$-0.00
10-Day Avg Trading Volume13.22M
EPS Excl Extra (TTM)$-0.00
EPS (Annual)$-0.00
ROI (Annual)-7.15%
Gross Margin (Annual)80.51%
Net Profit Margin (5Y Avg)-311.21%
Cash / Share (Quarterly)$0.01
Revenue Growth QoQ (YoY)-98.35%
ROA (Last FY)-4.95%
Revenue Growth TTM (YoY)-95.92%
EBITD / Share (TTM)$-0.00
ROE (5Y Avg)-125.37%
Operating Margin (TTM)-871.69%
Cash Flow / Share (Annual)$-0.00
P/B Ratio0.77x
P/B Ratio (Quarterly)0.82x
Net Income / Employee (Annual)$-84,400
EV / Revenue (TTM)17.68x
Net Interest Coverage (TTM)-0.28x
ROA (TTM)-4.82%
EV / EBITDA (TTM)2.46x
EPS Incl Extra (Annual)$-0.00
Current Ratio (Annual)1.95x
Quick Ratio (Quarterly)1.76x
3-Month Avg Trading Volume5.44M
52-Week Price Return136.20%
Revenue / Employee (TTM)$49,200
Tangible BV / Share (Quarterly)$0.00
P/S Ratio (Annual)11.84x
Asset Turnover (Annual)0.03x
52-Week High$3.90
Operating Margin (5Y Avg)-413.00%
EPS Excl Extra (Annual)$-0.00
CapEx CAGR (5Y)-5.85%
Tangible BV CAGR (5Y)-30.76%
26-Week Price Return-10.53%
Quick Ratio (Annual)1.76x
13-Week Price Return6.25%
Total Debt / Equity (Annual)0.56x
Current Ratio (Quarterly)1.95x
Enterprise Value$20.87M
Asset Turnover (TTM)0.03x
Book Value / Share Growth (5Y)-35.58%
Revenue / Employee (Annual)$49,200
Pretax Margin (Annual)-171.69%
Cash / Share (Annual)$0.01
3-Month Return Std Dev93.23%
Gross Margin (5Y Avg)62.71%
Net Income / Employee (TTM)$-84,300
ROE (Last FY)-11.13%
Net Interest Coverage (Annual)0.52x
EPS Basic Excl Extra (Annual)$-0.00
Receivables Turnover (TTM)0.94x
Total Debt / Equity (Quarterly)0.56x
EPS Incl Extra (TTM)$-0.00
ROI (TTM)-6.38%
P/S Ratio (TTM)11.84x
Pretax Margin (5Y Avg)-311.21%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.00
Price vs S&P 500 (52W)149.95%
Year-to-Date Return6.25%
5-Day Price Return21.43%
EPS Normalized (Annual)$-0.00
ROA (5Y Avg)-37.88%
Net Profit Margin (Annual)-171.69%
Month-to-Date Return13.33%
Cash Flow / Share (TTM)$-0.18
EBITD / Share (Annual)$-0.00
Operating Margin (Annual)-871.78%
LT Debt / Equity (Annual)0.25x
ROI (5Y Avg)-72.09%
LT Debt / Equity (Quarterly)0.25x
EPS Basic Excl Extra (TTM)$-0.00
P/TBV (Quarterly)8.12x
P/B Ratio (Annual)0.82x
Inventory Turnover (TTM)0.09x
Pretax Margin (TTM)-171.44%
Book Value / Share (Annual)$0.01
Price vs S&P 500 (13W)-3.50%
Beta0.58x
P/FCF (Annual)1.36x
Revenue / Share (TTM)$0.00
ROE (TTM)-10.27%
52-Week Low$1.10
vGradeB
gGradeF
mGradeB
vgmGradeC
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BLRXBioLineRX Ltd | B | F | B | $3.48 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
BioLine Rx is a commercial-stage biopharmaceutical company developing oncology-focused therapies. The company's pipeline includes two clinical-stage candidates: motixafortide (BL-8040), a peptide targeting stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent for solid tumors. The company also maintains a legacy product, BL-5010, for skin lesions, and has generated revenue through milestone payments and out-licensing agreements.